Abeliovich A, Gitler AD. Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature. 2016;539(7628):207–216. [PubMed: 27830778]

Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine. 2018;379(1):11–21. [PubMed: 29972753]

Amado DA, Rieders JM, Diatta F, Hernandez-Con P, Singer A, Mak JT, Zhang J, Lancaster E, Davidson BL, Chen-Plotkin AS. AAV-mediated progranulin delivery to a mouse model of progranulin deficiency causes T cell-mediated toxicity. Molecular Therapy. 2019;27(2):465–478. [PMC free article: PMC6369714] [PubMed: 30559071]

Banez-Coronel M, Ayhan F, Tarabochia AD, Zu T, Perez BA, Tusi SK, Pletnikova O, Borchelt DR, Ross CA, Margolis RL, Yachnis AT, Troncoso JC, Ranum LP. RAN translation in Huntington disease. Neuron. 2015;88(4):667–677. [PMC free article: PMC4684947] [PubMed: 26590344]

Bedbrook CN, Yang KK, Robinson JE, Gradinaru V, Arnold FH. Machine learning-guided channelrhodopsin engineering enables minimally-invasive optogenetics. Nature Methods. In press [PMC free article: PMC6858556] [PubMed: 31611694]

Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, McCague S, Pierce EA, Chen Y, Bennicelli JL, Zhu X, Ying GS, Sun J, Wright JF, Auricchio A, Simonelli F, Shindler KS, Mingozzi F, High KA, Maguire AM. AAV2 gene therapy readministration in three adults with congenital blindness. Science Translational Medicine. 2012;4(120):120ra115. [PMC free article: PMC4169122] [PubMed: 22323828]

Bennicelli J, Wright JF, Komaromy A, Jacobs JB, Hauck B, Zelenaia O, Mingozzi F, Hui D, Chung D, Rex TS, Wei Z, Qu G, Zhou S, Zeiss C, Arruda VR, Acland GM, Dell'Osso LF, High KA, Maguire AM, Bennett J. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Molecular Therapy. 2008;16(3):458–465. [PMC free article: PMC2842085] [PubMed: 18209734]

Betancur C, Buxbaum JD. SHANK3 haploinsufficiency: A “common” but under-diagnosed highly penetrant monogenic cause of autism spectrum disorders. Molecular Autism. 2013;4(1):17. [PMC free article: PMC3695795] [PubMed: 23758743]

Bevan AK, Duque S, Foust KD, Morales PR, Braun L, Schmelzer L, Chan CM, McCrate M, Chicoine LG, Coley BD, Porensky PN, Kolb SJ, Mendell JR, Burghes AH, Kaspar BK. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Molecular Therapy. 2011;19(11):1971–1980. [PMC free article: PMC3222525] [PubMed: 21811247]

Buchman AS, Yu L, Wilson RS, Leurgans SE, Nag S, Shulman JM, Barnes LL, Schneider JA, Bennett DA. Progressive Parkinsonism in older adults is related to the burden of mixed brain pathologies. Neurology. 2019;92(16):e1821–e1830. [PMC free article: PMC6550497] [PubMed: 30894446]

Challis RC, Kumar SR, Chan KY, Challis C, Beadle K, Jang MJ, Kim HM, Rajendran PS, Tompkins JD, Shivkumar K, Deverman BE, Gradinaru V. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nature Protocols. 2019;14:379–414. [PubMed: 30626963]

Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL, Sanchez-Guardado L, Lois C, Mazmanian SK, Deverman BE, Gradinaru V. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nature Neuroscience. 2017;20(8):1172–1179. [PMC free article: PMC5529245] [PubMed: 28671695]

Chatterjee D, Bhatt M, Butler D, De Genst E, Dobson CM, Messer A, Kordower JH. Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson's disease model. npj Parkinson's Disease. 2018;4:25. [PMC free article: PMC6105584] [PubMed: 30155513]

Christopher PP, Appelbaum PS, Truong D, Albert K, Maranda L, Lidz C. Reducing therapeutic misconception: A randomized intervention trial in hypothetical clinical trials. PLoS ONE. 2017;12(9):e0184224. [PMC free article: PMC5607126] [PubMed: 28931031]

Chu Y, Buchman AS, Olanow CW, Kordower JH. Do subjects with minimal motor features have prodromal Parkinson disease? Annals of Neurology. 2018;83(3):562–574. [PMC free article: PMC5867270] [PubMed: 29420861]

Chung DC, McCague S, Yu ZF, Thill S, DiStefano-Pappas J, Bennett J, Cross D, Marshall K, Wellman J, High KA. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clinical & Experimental Ophthalmology. 2018;46(3):247–259. [PMC free article: PMC5764825] [PubMed: 28697537]

Dahl M, Doyle A, Olsson K, Mansson JE, Marques ARA, Mirzaian M, Aerts JM, Ehinger M, Rothe M, Modlich U, Schambach A, Karlsson S. Lentiviral gene therapy using cellular promoters cures Type 1 Gaucher disease in mice. Molecular Therapy. 2015;23(5):835–844. [PMC free article: PMC4427872] [PubMed: 25655314]

Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2015;519(7542):223–228. [PMC free article: PMC5955210] [PubMed: 25533962]

Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, Wu WL, Yang B, Huber N, Pasca SP, Gradinaru V. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nature Biotechnology. 2016;34(2):204–209. [PMC free article: PMC5088052] [PubMed: 26829320]

DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, Zanardi TA, Kordasiewicz HB, Swayze EE, Bennett CF, Diamond MI, Miller TM. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Science Translational Medicine. 2017;9(374):eaag0481. [PMC free article: PMC5792300] [PubMed: 28123067]

Duque SI, Arnold WD, Odermatt P, Li X, Porensky PN, Schmelzer L, Meyer K, Kolb SJ, Schumperli D, Kaspar BK, Burghes AH. A large animal model of spinal muscular atrophy and correction of phenotype. Annals of Neurology. 2015;77(3):399–414. [PMC free article: PMC4453930] [PubMed: 25516063]

Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: Progress and challenges. Neurotherapeutics. 2015;12(2):290–302. [PMC free article: PMC4404441] [PubMed: 25413156]

FDA (Food and Drug Administration). May 24, 2019 approval letter—zolgensmsa. 2019. [May 25, 2019]. https://www​.fda.gov/media​/126130/download.

Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, Kang PB, Foley AR, Yang ML, Martens WB, Oskoui M, Glanzman AM, Flickinger J, Montes J, Dunaway S, O'Hagen J, Quigley J, Riley S, Benton M, Ryan PA, Montgomery M, Marra J, Gooch C, De Vivo DC. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810–817. [PMC free article: PMC4155049] [PubMed: 25080519]

Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, Norris DA, Xia S, Bennett CF, Bishop KM. Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study. The Lancet. 2016;388(10063):3017–3026. [PubMed: 27939059]

Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, Group ES. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. New England Journal of Medicine. 2017;377(18):1723–1732. [PubMed: 29091570]

Flytzanis NC, Bedbrook CN, Chiu H, Engqvist MK, Xiao C, Chan KY, Sternberg PW, Arnold FH, Gradinaru V. Archaerhodopsin variants with enhanced voltage-sensitive fluorescence in mammalian and Caenorhabditis elegans neurons. Nature Communications. 2014;5:4894. [PMC free article: PMC4166526] [PubMed: 25222271]

Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT, Morales PR, Rich MM, Burghes AH, Kaspar BK. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nature Biotechnology. 2010;28(3):271–274. [PMC free article: PMC2889698] [PubMed: 20190738]

Gao FB, Richter JD. Microsatellite expansion diseases: Repeat toxicity found in translation. Neuron. 2017;93(2):249–251. [PubMed: 28103472]

Garrison LP, Jackson T, Paul D, Kenston M. Value-based pricing for emerging gene therapies: The economic case for a higher cost-effectiveness threshold. Journal of Managed Care & Specialty Pharmacy. 2019;25(7):793–799. [PMC free article: PMC10397597] [PubMed: 30784347]

Gaugler T, Klei L, Sanders SJ, Bodea CA, Goldberg AP, Lee AB, Mahajan M, Manaa D, Pawitan Y, Reichert J, Ripke S, Sandin S, Sklar P, Svantesson O, Reichenberg A, Hultman CM, Devlin B, Roeder K, Buxbaum JD. Most genetic risk for autism resides with common variation. Nature Genetics. 2014;46(8):881–885. [PMC free article: PMC4137411] [PubMed: 25038753]

Geschwind DH, Konopka G. Neuroscience in the era of functional genomics and systems biology. Nature. 2009;461(7266):908–915. [PMC free article: PMC3645852] [PubMed: 19829370]

Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, McCown TJ, Li W. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Molecular Therapy. 2010;18(3):570–578. [PMC free article: PMC2831133] [PubMed: 20040913]

Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett Syndrome. Science. 2007;315(5815):1143–1147. [PMC free article: PMC7610836] [PubMed: 17289941]

Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, Kass N, King NMP, Lidz CW, Miller FG, Nelson DK, Peppercorn J, Rothschild BB, Sankar P, Wilfond BS, Zimmer CR. Clinical trials and medical care: Defining the therapeutic misconception. PLoS Medicine. 2007;4(11):e324. [PMC free article: PMC2082641] [PubMed: 18044980]

Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, Krainer AR. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes & Development. 2010;24(15):1634–1644. [PMC free article: PMC2912561] [PubMed: 20624852]

Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardinas AF, Rajagopal VM, Als TD, Nguyen HT, Girdhar K, Boocock J, Roussos P, Fromer M, Kramer R, Domenici E, Gamazon ER, Purcell S. CommonMind Consortium, The Schizophrenia Working Group of the Psychiatric Genomics Consortium, iPSYCH-GEMS Schizophrenia Working Group. Demontis D, Borglum AD, Walters JTR, O'Donovan MC, Sullivan P, Owen MJ, Devlin B, Sieberts SK, Cox NJ, Im HK, Sklar P, Stahl EA. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. Nature Genetics. 2019;51(4):659–674. [PMC free article: PMC7034316] [PubMed: 30911161]

ICER (Institute for Clinical and Economic Review). Spinraza and zolgensma for spinal muscular atrophy: Effectiveness and value: Final evidence report. 2019. [August 9, 2019]. https://icer-review​.org​/wp-content/uploads​/2018/07/ICER_SMA_Final​_Evidence_Report_040319.pdf.

Jonsen AR. The god squad and the origins of transplantation ethics and policy. The Journal of Law, Medicine & Ethics. 2007;35(2):238–240. [PubMed: 17518848]

Kaltenboeck A, Bach PB. Value-based pricing for drugs: Theme and variations. JAMA. 2018;319(21):2165–2166. [PubMed: 29710320]

Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB, Oskoui M, Constantinescu A, Gooch CL, Foley AR, Yang ML, Tawil R, Chung WK, Martens WB, Montes J, Battista V, O'Hagen J, Dunaway S, Flickinger J, Quigley J, Riley S, Glanzman AM, Benton M, Ryan PA, Punyanitya M, Montgomery MJ, Marra J, Koo B, De Vivo DC. Muscle Study Group, and Pediatric Neuromuscular Clinical Research Network for Spinal Muscular Atrophy. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79(18):1889–1897. [PMC free article: PMC3525313] [PubMed: 23077013]

Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nature Biotechnology. 2017;35(3):238–248. [PMC free article: PMC5517098] [PubMed: 28244990]

Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Iannaccone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT. and NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. Natural history of infantile-onset spinal muscular atrophy. Annals of Neurology. 2017;82(6):883–891. [PMC free article: PMC5776712] [PubMed: 29149772]

Kole R, Krieg AM. Exon skipping therapy for Duchenne muscular dystrophy. Advanced Drug Delivery Reviews. 2015;87:104–107. [PubMed: 25980936]

Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Annals of Neurology. 1999;46(3):419–424. [PubMed: 10482276]

Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 2000;290(5492):767–773. [PubMed: 11052933]

Kornegay JN. The golden retriever model of Duchenne muscular dystrophy. Skeletal Muscle. 2017;7(1):9. [PMC free article: PMC5438519] [PubMed: 28526070]

Li L, Dimitriadis EK, Yang Y, Li J, Yuan Z, Qiao C, Beley C, Smith RH, Garcia L, Kotin RM. Production and characterization of novel recombinant adeno-associated virus replicative-form genomes: A eukaryotic source of DNA for gene transfer. PLoS ONE. 2013;8(8):e69879. [PMC free article: PMC3731302] [PubMed: 23936358]

Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR. and International Genetics of Parkinson Disease Progression Consortium. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Annals of Neurology. 2016a;80(5):674–685. [PMC free article: PMC5244667] [PubMed: 27717005]

Liu W, Zhao L, Blackman B, Parmar M, Wong MY, Woo T, Yu F, Chiuchiolo MJ, Sondhi D, Kaminsky SM, Crystal RG, Paul SM. Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice. Journal of Neuroscience. 2016b;36(49):12425–12435. [PMC free article: PMC6601971] [PubMed: 27927959]

Lo Bianco C, Deglon N, Pralong W, Aebischer P. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiology of Disease. 2004;17(2):283–289. [PubMed: 15474365]

Lundstrom K. Viral vectors in gene therapy. Diseases. 2018;6(2):42. [PMC free article: PMC6023384] [PubMed: 29883422]

Mei Y, Monteiro P, Zhou Y, Kim JA, Gao X, Fu Z, Feng G. Adult restoration of Shank3 expression rescues selective autistic-like phenotypes. Nature. 2016;530(7591):481–484. [PMC free article: PMC4898763] [PubMed: 26886798]

Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-dose gene-replacement therapy for spinal muscular atrophy. New England Journal of Medicine. 2017;377(18):1713–1722. [PubMed: 29091557]

Mintrom M, Bollard R. Governing controversial science: Lessons from stem cell research. Policy and Society. 2009;28(4):301–314.

Monteys AM, Ebanks SA, Keiser MS, Davidson BL. CRISPR/Cas9 editing of the mutant Huntingtin allele in vitro and in vivo. Molecular Therapy. 2017;25(1):12–23. [PMC free article: PMC5363210] [PubMed: 28129107]

Morabito G, Giannelli SG, Ordazzo G, Bido S, Castoldi V, Indrigo M, Cabassi T, Cattaneo S, Luoni M, Cancellieri C, Sessa A, Bacigaluppi M, Taverna S, Leocani L, Lanciego JL, Broccoli V. AAV-PHP.B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy. Molecular Therapy. 2017;25(12):2727–2742. [PMC free article: PMC5768559] [PubMed: 28882452]

Olson EJ, Hartsough LA, Landry BP, Shroff R, Tabor JJ. Characterizing bacterial gene circuit dynamics with optically programmed gene expression signals. Nature Methods. 2014;11(4):449–455. [PubMed: 24608181]

Pacione M, Siskind CE, Day JW, Tabor HK. Perspectives on Spinraza (nusinersen) treatment study: Views of individuals and parents of children diagnosed with spinal muscular atrophy. Journal of Neuromuscular Diseases. 2019;6(1):119–131. [PubMed: 30594933]

Palfi S, Gurruchaga JM, Lepetit H, Howard K, Ralph GS, Mason S, Gouello G, Domenech P, Buttery PC, Hantraye P, Tuckwell NJ, Barker RA, Mitrophanous KA. Long-term follow-up of a phase I/II study of prosavin, a lentiviral vector gene therapy for Parkinson's disease. Human Gene Therapy Clinical Development. 2018;29(3):148–155. [PMC free article: PMC6157351] [PubMed: 30156440]

Paton DM. Nusinersen: Antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. Drugs of Today (Barcelona, Spain: 1998). 2017;53(6):327–337. [PubMed: 28799578]

Power RA, Kyaga S, Uher R, MacCabe JH, Langstrom N, Landen M, McGuffin P, Lewis CM, Lichtenstein P, Svensson AC. Fecundity of patients with schizophrenia, autism, bipolar disorder, depression, anorexia nervosa, or substance abuse vs their unaffected siblings. JAMA Psychiatry. 2013;70(1):22–30. [PubMed: 23147713]

Rayaprolu V, Kruse S, Kant R, Venkatakrishnan B, Movahed N, Brooke D, Lins B, Bennett A, Potter T, McKenna R, Agbandje-McKenna M, Bothner B. Comparative analysis of adeno-associated virus capsid stability and dynamics. Journal of Virology. 2013;87(24):13150–13160. [PMC free article: PMC3838259] [PubMed: 24067976]

Rudnik-Schoneborn S, Berg C, Zerres K, Betzler C, Grimm T, Eggermann T, Eggermann K, Wirth R, Wirth B, Heller R. Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: Implications for clinical trials and genetic counselling. Clinical Genetics. 2009;76(2):168–178. [PubMed: 19780763]

Rund BR. The research evidence for schizophrenia as a neurodevelopmental disorder. Scandinavian Journal of Psychology. 2018;59(1):49–58. [PubMed: 29356007]

Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. The Lancet. 2017a;390(10097):849–860. [PMC free article: PMC5726391] [PubMed: 28712537]

Russell SR, Bennett J, Wellman JA, Chung DC, High KA, Yu Z, Tillman A, Maguire AM. RPE65-mediated inherited retinal disease. Poster presented at the Association for Research in Vision and Ophthalmology Annual Meeting, May 7-11, 2017. Baltimore, MD: 2017b. Year 2 results for a phase 3 trial of voretigene neparvovec in biallelic.

Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Treleaven CM, Bu J, Sweet L, Passini MA, Dodge JC, Yu WH, Sidman RL, Cheng SH, Shihabuddin LS. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for Parkinsonism and other Gaucher-related synucleinopathies. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(9):3537–3542. [PMC free article: PMC3587272] [PubMed: 23297226]

Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, Detloff PJ, Housman DE, Bates GP. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(6):2366–2370. [PMC free article: PMC3568346] [PubMed: 23341618]

Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ. 2001;164(11):1612. [PMC free article: PMC81135] [PubMed: 11402803]

Sidransky E, Samaddar T, Tayebi N. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009;73(17):1424–1425. author reply 1425-1426. [PubMed: 19858467]

Steinbrook R. The Gelsinger case. In: Emanuel EJ, Grady CG, Crouch RA, Lie RK, Miller FG, Wendler DD, editors. The Oxford textbook of clinical research ethics. New York: Oxford University Press; 2008. pp. 110–120.

Sun J, Carlson-Stevermer J, Das U, Shen M, Delenclos M, Snead AM, Koo SY, Wang L, Qiao D, Loi J, Petersen AJ, Stockton M, Bhattacharyya A, Jones MV, Zhao X, McLean PJ, Sproul AA, Saha K, Roy S. CRISPR/Cas9 editing of APP C-terminus attenuates beta-cleavage and promotes alpha-cleavage. Nature Communications. 2019;10(1):53. [PMC free article: PMC6318289] [PubMed: 30604771]